169 related articles for article (PubMed ID: 21282280)
1. Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease.
Grossberg G; Meng X; Olin JT
Am J Alzheimers Dis Other Demen; 2011 Feb; 26(1):65-71. PubMed ID: 21282280
[TBL] [Abstract][Full Text] [Related]
2. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.
Cummings JL; Ferris SH; Farlow MR; Olin JT; Meng X
Dement Geriatr Cogn Disord; 2010; 29(5):406-12. PubMed ID: 20502014
[TBL] [Abstract][Full Text] [Related]
3. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
4. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
Grossberg GT; Olin JT; Somogyi M; Meng X
Int J Clin Pract; 2011 Apr; 65(4):465-71. PubMed ID: 21309961
[TBL] [Abstract][Full Text] [Related]
5. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
[TBL] [Abstract][Full Text] [Related]
6. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia.
Farlow MR; Grossberg GT; Sadowsky CH; Meng X; Somogyi M
CNS Neurosci Ther; 2013 Oct; 19(10):745-52. PubMed ID: 23924050
[TBL] [Abstract][Full Text] [Related]
7. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R
Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease.
Grossberg G; Cummings J; Frölich L; Bellelli G; Molinuevo JL; Krahnke T; Strohmaier C
Am J Alzheimers Dis Other Demen; 2013 Sep; 28(6):583-91. PubMed ID: 23982674
[TBL] [Abstract][Full Text] [Related]
9. Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).
Zhang ZX; Hong Z; Wang YP; He L; Wang N; Zhao ZX; Zhao G; Shang L; Weisskopf M; Callegari F; Strohmaier C
CNS Neurosci Ther; 2016 Jun; 22(6):488-96. PubMed ID: 27012596
[TBL] [Abstract][Full Text] [Related]
10. Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor.
Grossberg GT; Farlow MR; Meng X; Velting DM
Curr Alzheimer Res; 2015; 12(1):53-60. PubMed ID: 25523430
[TBL] [Abstract][Full Text] [Related]
11. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study.
Ballard C; Sauter M; Scheltens P; He Y; Barkhof F; van Straaten EC; van der Flier WM; Hsu C; Wu S; Lane R
Curr Med Res Opin; 2008 Sep; 24(9):2561-74. PubMed ID: 18674411
[TBL] [Abstract][Full Text] [Related]
13. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living.
Olin JT; Aarsland D; Meng X
Dement Geriatr Cogn Disord; 2010; 29(6):510-5. PubMed ID: 20523050
[TBL] [Abstract][Full Text] [Related]
14. Rivastigmine for Alzheimer's disease.
Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
[TBL] [Abstract][Full Text] [Related]
15. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.
Blesa R; Ballard C; Orgogozo JM; Lane R; Thomas SK
Neurology; 2007 Jul; 69(4 Suppl 1):S23-8. PubMed ID: 17646620
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses.
Alva G; Grossberg GT; Schmitt FA; Meng X; Olin JT
Int J Geriatr Psychiatry; 2011 Apr; 26(4):356-63. PubMed ID: 21312297
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
[TBL] [Abstract][Full Text] [Related]
18. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models.
Nagy B; Brennan A; Brandtmüller A; Thomas SK; Sullivan SD; Akehurst R
Int J Geriatr Psychiatry; 2011 May; 26(5):483-94. PubMed ID: 20845395
[TBL] [Abstract][Full Text] [Related]
19. Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease.
Lee JH; Sevigny J
Alzheimer Dis Assoc Disord; 2011; 25(1):58-62. PubMed ID: 20975519
[TBL] [Abstract][Full Text] [Related]
20. Rivastigmine for Alzheimer's disease.
Birks JS; Grimley Evans J
Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]